Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

The blockade of immune checkpoints in cancer immunotherapy

2012 • 12,062 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2012 • 7,361 citations

Cancer immunoediting: from immunosurveillance to tumor escape

2002 • 4,911 citations

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

2000 • 4,853 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Cancer immunotherapy comes of age

2011 • 3,453 citations

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

2001 • 2,746 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 • 2,721 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

2012 • 1,988 citations

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

2009 • 1,604 citations

Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

2007 • 1,603 citations

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

1996 • 1,473 citations

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8⁺T lymphocytes are prognostic factors of human ovarian cancer

2007 • 1,317 citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

2003 • 1,289 citations

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

2006 • 1,254 citations

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

2001 • 1,108 citations

Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production

2003 • 933 citations

B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

2001 • 850 citations

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

2007 • 843 citations

Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up

2006 • 826 citations

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

2009 • 770 citations

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

2005 • 758 citations

Melanoma genome sequencing reveals frequent PREX2 mutations

2012 • 734 citations

Rituximab: Mechanism of Action

2010 • 707 citations

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

2004 • 664 citations

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

2008 • 653 citations

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

2006 • 647 citations

PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2

2002 • 646 citations

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

2010 • 632 citations

SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA

2000 • 610 citations

The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

2006 • 570 citations

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

2007 • 553 citations

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

2007 • 506 citations

Coordinated protein sorting, targeting and distribution in polarized cells

2008 • 491 citations

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

2006 • 474 citations

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2011 • 470 citations

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

2006 • 447 citations

PD-1 and its ligands in T-cell immunity

2007 • 419 citations

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

2004 • 413 citations

PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata

2007 • 407 citations

Expression of the B7 - related molecule B7 - H1 by glioma cells: a potential mechanism of immune paralysis

2003 • 370 citations

Development and Characterization of Clinical-Grade ⁸⁹Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

2009 • 317 citations

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

2010 • 311 citations

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

2012 • 284 citations

PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues

2007 • 237 citations

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders

2009 • 209 citations

A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism

2007 • 198 citations

Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2

2010 • 182 citations

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

2011 • 179 citations

Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy

2007 • 176 citations

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

2008 • 170 citations

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

2009 • 169 citations

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

2008 • 168 citations

Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma

2011 • 163 citations

The origins of cancer robustness and evolvability

2010 • 161 citations

Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma

2010 • 156 citations

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

2010 • 154 citations

Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

2011 • 134 citations

The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo

2011 • 125 citations

Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications inDe novoAcute Myeloid Leukemia

2005 • 114 citations

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

2008 • 113 citations

Microenvironmental Regulation of Cancer Stem Cell Phenotypes

2012 • 104 citations

Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma

2007 • 103 citations

Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin

2010 • 94 citations

Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors

2011 • 87 citations

Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.

2010 • 86 citations

Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.

2012 • 84 citations

Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer

2010 • 61 citations

Autoimmunity and treatment outcome in melanoma

2010 • 54 citations

A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma.

2011 • 51 citations

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

2011 • 29 citations

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).

2012 • 18 citations

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

2012 • 14 citations

Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL).

2012 • 14 citations

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

2012 • 12 citations